Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: Preliminary results

Journal of Chemotherapy

Volumn 15, Issue 1, 2003, Pages 66-70

  Valerio, Giuseppe ^a,c   Bracciale, P ^a   Manisco, V ^b   Quitadamo, M ^b   Legari, G ^a   Bellanova, S ^a  

^a Reparto di Pneumologia   (Italy)

^b Servizio di Pneumologia   (Italy)

^c Ospedale N Melli   (Italy)

Author keywords

Moxifloxacin; Quinolones; TB; Tuberculosis

Indexed keywords

AMINOTRANSFERASE; ANTIBODY; ANTIGEN; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD GAS ANALYSIS; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; ENZYME ASSAY; FEMALE; FOLLOW UP; FUNCTION TEST; HEPATITIS; HUMAN; LEUKEMIA; LYMPHOMA; MALE; MULTIDRUG RESISTANCE; PLEURISY; REMISSION; SPUTUM ANALYSIS; STANDARD; THORAX RADIOGRAPHY; TIME; TOXICITY; TREATMENT OUTCOME; TUBERCULOSIS; UROGENITAL TRACT DISEASE;

EID: 0037299916     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.1.66     Document Type: Article

References (7)

1. The WHO-IUALTD. Anti-tuberculosis drug resistance in the world. World Health Organization, Geneva, 1997.
2. Truffolt-Pernot JB, Grosset J. In vitro and in vivo activities of sparfloxacin against mycobacterium tuberculosis. Tubercle 1991; 72 (3): 181-6.
3. Hoffner SE, Gezelius L, Olsson-Liliùjequist B. In vitro activities of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997; 40 (6): 885-8.
4. Gillespie SH. Preclinical microbiology: mycobacteria. In: First International Moxifloxacin Symposium. By L. Mandell, Berlin: Springer Verlag, 1999: 37-41.
5. Lounis N, Masio C, Truffolt-Permnot C, Bonnafous O, Grosset J. In vitro and in vivo activities of moxifloxacin against mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42 (8): 2066-9.
6. Lounis N, Bentoucha A, Truffolt-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001; 45 (12): 3482-6.
7. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin, a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999; 43 (1): 85-9.